Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Peter L. Greenberg

Division of Hematology

Stanford University Cancer Center

Stanford

CA 94305

USA

[email]@stanford.edu

Name/email consistency: high

[Claim this account]

Affiliations

Division of Hematology, Stanford University Cancer Center, Stanford, CA 94305, USA. 2006 - 2010
Stanford University Cancer Center, CA 94305, USA. 2008 - 2009
Hematology Division, Palo Alto VA Health Care System, Stanford University Medical Center, Palo Alto, USA. 2001 - 2004

References

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Greenberg, P.L., Koller, C.A., Cabantchik, Z.I., Warsi, G., Glynos, T., Paley, C., Schiffer, C. Leuk. Res. (2010) [Pubmed]
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Greenberg, P.L., Sun, Z., Miller, K.B., Bennett, J.M., Tallman, M.S., Dewald, G., Paietta, E., van der Jagt, R., Houston, J., Thomas, M.L., Cella, D., Rowe, J.M. Blood (2009) [Pubmed]
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Greenberg, P.L., Cosler, L.E., Ferro, S.A., Lyman, G.H. J. Natl. Compr. Canc. Netw (2008) [Pubmed]
Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Greenberg, P.L. J. Natl. Compr. Canc. Netw (2006) [Pubmed]
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). Greenberg, P.L., Lee, S.J., Advani, R., Tallman, M.S., Sikic, B.I., Letendre, L., Dugan, K., Lum, B., Chin, D.L., Dewald, G., Paietta, E., Bennett, J.M., Rowe, J.M. J. Clin. Oncol. (2004) [Pubmed]
Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. Greenberg, P. Lancet (2001) [Pubmed]
Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. Greenberg, P. Ann. Rheum. Dis. (2001) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.